Mediar Therapeutics

United States - Cambridge, MA

• 15/03/2023
• Unknown
• $105,000,000

Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease progression.

Mediar was founded based on a deep understanding of the complex science underlying fibrosis onset and progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar is derisking the path forward for fibrosis therapies in clinical development.

For more information, contact info@mediartx.com

Related People

Rahul BallalFounder

United States - Boston, Massachusetts

Rahul is a biotech executive with more than 15 years of experience in building companies, business development, and company financing. Rahul previously served as Imara’s (NASDAQ: IMRA) president and chief executive officer from Series A, through an IPO, raising $200MM in capital and completing a merger with Enliven Therapeutics (NASDAQ: ELVN) . Prior to this role at Imara, he served as chief business officer of Northern Biologics and as an entrepreneur-in-residence at Versant Ventures. Previously, Rahul was vice president of business development at Flexion Therapeutics (FLXN) and an associate at ASM ventures. Additionally, Rahul serves on the Board of Directors of Enliven Therapeutics (NASDAQ: ELVN), Agios Pharmaceuticals (NASDAQ: AGIO), and Vaderis Therapeutics AG. Rahul holds a Ph.D. in biochemistry from Georgetown University, an MS in bioinformatics from Johns Hopkins University and a BS in biology from Brown University.

LinkedIn https://www.linkedin.com/in/ballal/